Literature DB >> 19620856

Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a case-control study in a Spanish population.

Pablo Román-García1, Eliecer Coto, Julián R Reguero, Jorge B Cannata-Andía, Iñigo Lozano, Pablo Avanzas, César Morís, Isabel Rodríguez.   

Abstract

OBJECTIVES: Inherited and acquired risk factors contribute to the development of the atherosclerotic lesion and its most common clinical manifestation, myocardial infarction (MI). Multiple studies have suggested a role for matrix metalloproteinases (MMPs) in atherosclerosis, and several functional polymorphisms in the MMP-1 gene have been linked to the risk of MI. The aim of this study was to evaluate the association between MMP-1 promoter polymorphisms and early MI in a Spanish cohort.
METHODS: We carried out a case-control study with 261 unrelated patients who had suffered an MI before 55 years of age and 194 healthy controls, all male and smokers. The genotypes for the three MMP-1 promoter polymorphisms -1607 1G/2G, -519 A/G, and -340 T/C were determined through PCR-restriction fragment length polymorphism. Allelic, genotypic, and haplotypic frequencies were statistically compared between groups.
RESULTS: Frequencies of the three polymorphisms did not differ between patients and controls. The -1607 1G/2G and -519 A/G variants were in linkage disequilibrium. Analysis of the haplotype frequencies showed significant associations of the 2G(-1607)-G(-519)-T(-340) (odds ratio = 2.40; 95% confidence interval = 1.27-4.55; P<0.006) and 1G(-1607)-G(-519)-T(-340) (odds ratio = 0.68; 95% confidence interval = 0.50-0.94; P<0.05) haplotypes with the risk of early MI.
CONCLUSION: MMP-1 promoter polymorphisms are associated with the risk of early MI in a Spanish population of smoking males.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620856     DOI: 10.1097/MCA.0b013e32832fa9cf

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  6 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 3.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

4.  Association of matrix metalloproteinase-1 -519A/G polymorphism with acute coronary syndrome: a meta-analysis.

Authors:  Pengyu Jia; Nan Wu; Xiaowen Zhang; Dalin Jia
Journal:  Int J Clin Exp Med       Date:  2015-04-15

5.  Association of MMP1 and MMP3 haplotypes with myocardial infarction and echocardiographic parameters of the left ventricle.

Authors:  Tamara Djuric; Jovana Kuveljic; Ana Djordjevic; Milica Dekleva; Goran Stankovic; Aleksandra Stankovic; Maja Zivkovic
Journal:  Mol Genet Genomic Med       Date:  2022-08-01       Impact factor: 2.473

6.  MMP-1 promoter polymorphism is associated with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy.

Authors:  Bo Liu; Minxiao Yi; Yang Tang; Qingxu Liu; Hong Qiu; Yanmei Zou; Ping Peng; Lu Zhang; Chunping Hu; Xianglin Yuan
Journal:  Oncotarget       Date:  2016-10-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.